Streetbeat News

Regulatory

SPY

Federal Reserve's Waller stated that the inflation data over the last three months has been 'very good'. If the current trends continue, inflation will be back to target. He also mentioned that the real side of the economy is doing well, suggesting that the Fed can observe and decide on the rates.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 2:41 pm

SPY

Federal Reserve's Waller stated that long-term rates are determined by the market. He expressed concerns about the sustainability of a 6% deficit with low unemployment. He also noted the impact of issuance on yields and praised the resilience of the job market despite tight Fed policy.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 2:40 pm

EIS

SPY

USO

US intelligence suggests that key Iranian leaders were surprised by the recent Hamas attack in Israel, casting doubt on Iran's direct involvement in the assault. Despite Iran's long history of supporting Hamas, there is no evidence of direct planning or knowledge of the attack by Iran. The US continues to investigate the situation, with officials stating that Iran's provision of weapons and support to Hamas makes it broadly complicit in the attack. The Biden administration faces criticism from Republicans who claim the administration is soft on Iran and that the recent unfreezing of $6 billion in Iranian funds indirectly financed the assault. Treasury Secretary Janet Yellen has not ruled out refreezing the funds if Iran's involvement is confirmed.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 2:37 pm

INCY

Incyte (NASDAQ:INCY) has announced new results from its Phase 3 TRuE-V program, demonstrating the efficacy of continued treatment with Opzelura cream in nonsegmental vitiligo patients. The data shows that patients who initially experienced limited or no facial or total body repigmentation at six months achieved improved repigmentation after continued treatment with Opzelura for up to two years. The treatment was well-tolerated with no serious treatment-related adverse events reported.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 2:32 pm

TGTX

TG Therapeutics, Inc. (NASDAQ:TGTX) has presented data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS) at the 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting. The data highlights the unique attributes of BRIUMVI and includes the first data from the ENHANCE trial evaluating patients who switch from an IV anti-CD20 antibody to BRIUMVI.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 2:31 pm

SMCI

Supermicro's senior solutions manager, Alok Kumar Srivastav, highlighted the role of AI in the next industrial revolution during an interview with DIGITIMES Asia. He emphasized the importance of digital data creation, storage, and processing in AI development. Srivastav also discussed Supermicro's partnerships with Nvidia, Intel, and AMD, and the company's role in supplying computing units to major corporations across various industries. He predicted that AI adoption will become a necessity for survival in the modern marketplace.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 2:27 pm

EIS

SPY

USO

VGK

Russia's Energy Minister, Novak, has stated that Russia and Saudi Arabia have not discussed any action plan within OPEC+ in case of further escalation in the Middle East, according to Reuters citing IFAX.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 2:26 pm

EIS

FXI

USO

China's Middle East Special Envoy has stated that the top priority is to achieve an immediate ceasefire. This could potentially impact the stability of the region and consequently, the global markets.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 2:17 pm

MLTX

MoonLake Immunotherapeutics (NASDAQ:MLTX) has presented positive 12-week data from its Phase 2 MIRA trial of Nanobody Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress. The trial met its primary endpoint with a significantly higher proportion of patients treated with sonelokimab achieving HiSCR75 compared to those on placebo. The safety profile of sonelokimab was consistent with previously reported studies. The company anticipates 24-week data from the trial imminently.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 2:17 pm

URA

According to the EIA Administrator, the combined contribution of renewable and nuclear energy is expected to account for 55-60% of the global electricity supply by 2050. This prediction was cited by Reuters.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 1:53 pm